Related Experiment Videos
Tau Spread, Apolipoprotein E, Inflammation, and More: Rapidly Evolving Basic Science in Alzheimer Disease
Bianca Gonzalez1, Edsel M Abud2, Abigail M Abud2
1UCLA School of Nursing, Box 956919, Factor Building 6-266, Los Angeles, CA 90095, USA.
Neurologic Clinics
|April 16, 2017
Summary
Despite past failures in Alzheimer disease drug trials, recent preclinical research offers hope for novel therapies. Advances in amyloid-based treatments suggest a faster path toward successful clinical trials for Alzheimer disease.
Area of Science:
- Neuroscience
- Pharmacology
- Biomedical Research
Background:
- Alzheimer disease drug development has faced significant setbacks in human clinical trials.
- Translating promising laboratory research into effective treatments remains a slow process.
Purpose of the Study:
- To highlight rapidly advancing preclinical research topics for Alzheimer disease.
- To discuss the potential for novel and amyloid-based therapies to accelerate clinical success.
Main Methods:
- Review of selected preclinical research in Alzheimer disease.
- Analysis of advancements in drug targets and therapeutic strategies.
Main Results:
- Preclinical research is progressing rapidly in key areas relevant to Alzheimer disease.
- Amyloid-based and other novel therapeutic approaches show promise.
Conclusions:
- Decades of foundational work provide a basis for optimism in Alzheimer disease drug development.
- Advancements in preclinical research may expedite the transition of new therapies into successful clinical trials.